| Breast Carcinoma
Zoladex vs Trazimera
Side-by-side clinical, coverage, and cost comparison for breast carcinoma.Deep comparison between: Zoladex vs Trazimera with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrazimera has a higher rate of injection site reactions vs Zoladex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trazimera but not Zoladex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zoladex
Trazimera
At A Glance
SC injection
Every 28 days
GnRH agonist
IV infusion
Weekly or every 3 weeks
HER2/neu receptor antagonist
Indications
- Prostate carcinoma
- Endometriosis
- Abnormal uterine bleeding
- Breast Carcinoma
- Breast Carcinoma
- Gastric Adenocarcinoma
- Adenocarcinoma of the gastroesophageal junction
Dosing
Prostate carcinoma (Stage B2-C) 3.6 mg SC every 28 days starting 8 weeks before radiotherapy, in combination with flutamide, continued during radiation therapy; alternatively, a 10.8 mg depot may follow the initial 3.6 mg depot.
Prostate carcinoma (advanced) 3.6 mg SC every 28 days; intended for long-term administration.
Endometriosis 3.6 mg SC every 28 days for 6 months.
Abnormal uterine bleeding One or two 3.6 mg SC depots given 4 weeks apart; surgery performed at 4 weeks after one depot, or within 2-4 weeks after the second depot.
Breast Carcinoma 3.6 mg SC every 28 days; intended for long-term administration.
Breast Carcinoma (adjuvant) 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly for 12-18 weeks, then 6 mg/kg IV q3w to complete 52 weeks total; alternatively, 8 mg/kg loading dose over 90 min IV, then 6 mg/kg IV q3w for 52 weeks.
Breast Carcinoma (metastatic) 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly IV until disease progression.
Gastric Adenocarcinoma, Adenocarcinoma of the gastroesophageal junction 8 mg/kg loading dose over 90 min IV, then 6 mg/kg IV over 30-90 min q3w until disease progression.
Contraindications
- Known hypersensitivity to GnRH, GnRH agonist analogues, or any component of ZOLADEX
- Pregnancy (except when used for palliative treatment of advanced breast cancer)
—
Adverse Reactions
Most common (>10%) in men Hot flashes, sexual dysfunction, decreased erections, lower urinary tract symptoms
Most common (>20%) in women Hot flushes, headache, sweating, acne, emotional lability, depression, decreased libido, vaginitis, breast atrophy, seborrhea, peripheral edema
Serious Tumor flare, ureteral obstruction, spinal cord compression, pituitary apoplexy
Postmarketing Osteoporosis, bone fracture, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, transient ischemic attack, ovarian cyst, pituitary adenoma, SJS/TEN, DRESS, AGEP, erythema multiforme, psychotic disorders, suicidal ideation, convulsions
Most common Fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, myalgia
Serious Cardiomyopathy, severe infusion reactions, pulmonary toxicity, embryo-fetal toxicity, exacerbation of chemotherapy-induced neutropenia
Postmarketing Infusion reaction, oligohydramnios or oligohydramnios sequence, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Pharmacology
ZOLADEX is a synthetic decapeptide analogue of GnRH that inhibits pituitary gonadotropin secretion; chronic administration suppresses serum testosterone in males to castrate levels and reduces serum estradiol in females to postmenopausal levels, leading to regression of hormone-sensitive tumors and accessory sex organ regression.
Trastuzumab-qyyp is a HER2/neu receptor antagonist that inhibits proliferation of HER2-overexpressing human tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) preferentially on HER2-overexpressing cancer cells compared with cells that do not overexpress HER2.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zoladex
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Trazimera
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Zoladex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Trazimera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Zoladex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Trazimera
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Zoladex.
$0/fillfill
Trazimera Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZoladexView full Zoladex profile
TrazimeraView full Trazimera profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.